THERALASE TECHNOLOGIESLOGIE.INC

Action · CA88337V1004 · A0DLB7 (XTSX)

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur THERALASE TECHNOLOGIESLOGIE.INC

Pas de cours

Cours de clôture XTSX 29.04.2026: 0,31 CAD

29.04.2026 19:59

Cours actuels de THERALASE TECHNOLOGIESLOGIE.INC

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
TSX-V	TLT.V	CAD	29.04.2026 19:59	0,31 CAD	-0,02 CAD -6,15 %
UTC	TLTFF	USD	29.04.2026 19:57	0,22 USD	-0,02 USD -7,00 %
Quotrix	TTIRSN04.DUSD	EUR	29.04.2026 05:27	0,21 EUR	-
Düsseldorf	TTIRSN04.DUSB	EUR	28.04.2026 17:58	0,23 EUR	-

Flottant et Liquidité des Actions

Flottant Libre 92,42 %

Actions en Flottant 237,57 M

Actions en Circulation 257,06 M

Profil de l'entreprise pour THERALASE TECHNOLOGIESLOGIE.INC Action

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.